( Given its ability to detect a disease i...)Pharmacogenomic Market Gaining Greater Acceptance Across Europe,Health

Given its ability to detect a disease in its very early stage, consequently improving clinical outcomes, pharmacogenomic testing is slowly gaining greater acceptance across Europe . Furthermore, pharmacogenomic testing decreases the use of expensive therapies and invasive procedures, in addition to reducing bed occupancy and burden on the healthcare system. In Europe, age-related diseases such as cancer, Alzheimer's disease, stroke and heart failure represent the highest cost burden to the healthcare systems.

New analysis from Frost & Sullivan, European Personalised Medicine and Pharmacogenomics Market, finds that revenues in this market totalled $57.1 million in 2005, and are likely to reach $109.4 million in 2012.

"Considering the imminent benefits of pharmacogenomic testing, governments across Europe have initiated campaigns to encourage the population to be screened on certain types of diseases such as cancer, which has significantly helped better patient management," notes Frost & Sullivan Program Leader Dr. Fiona Rahman. "In the case of cancer, patients have more than 90 per cent five year survival rate if their condition is detected in the primary stages, and pharmacogenomic testing remains the foremost weapon in the fight against cancer."

Furthermore, medical communities are increasingly stressing on preventive medicine as the most efficacious and cost-effective approach to improving the quality of life. In addition, researchers have realised that the most effective way to combat diseases such as diabetes or cancer is to predict susceptibility and begin preventive treatment before the onset of the disease. Designing preventive screening programmes with the doctor will allow people to be in charge of their own health. Therefore, pharmacogenomics testing is seen to have tremendous market value.

Notwithstanding its benefits, inherent problems regarding time and cost associated with the development of diagno
'"/>




Page: 1 2 3
Related medicine news :

1. Panacea Biotech To Market Anthrax Vaccine
2. Ranbaxy Labs Entry Into Anti-Acne Market
3. FDA to bring about changes in Marketed Non-Steroidal Anti-Inflammatory Drugs
4. FDA To Set New Guidelines To Revise Drug Companies Marketing Tactics
5. Donated Mothers Milk To Hit The Market
6. New Four- in- one Vaccine For DTP & Hepatitis To Hit The Indian Market
7. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
8. Junk Food Marketing to be banned
9. Biovac, Hepatitis A Vaccine Marketed By Wockhardt
10. Government Should Restrict Junk Food Marketing
11. Canada May Not Permit Bextra To Reenter Market